KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study.

M Gartland, X Wang, Q Liao, B Li, F Du, M Krystal, A R Tenorio, A Pierce, J R Castillo-Mancilla

HIV Med 27(3) 386-396

PMID41387279
PMCIDPMC12968507
DOI10.1111/hiv.70154
发表日期2025-12-12
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 forest plot;FIGURE 2:非 KM 图。
摘要

摘要

OBJECTIVES: The gp120-directed attachment inhibitor fostemsavir was effective in people with multidrug-resistant (MDR) HIV-1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir-based regimens. In previous multivariable analyses, baseline CD4+ T-cell count, baseline log10 HIV-1 RNA and temsavir plasma concentration were associated with virologic response through 24 weeks. This expanded analysis evaluated predictors of the durability of response at Weeks 96 and 192. METHODS: BRIGHTE participant data (Randomized Cohort [RC], n = 272; Non-randomized Cohort, n = 99) were evaluated to examine baseline factors associated with virologic outcomes (HIV-1 RNA <40 copies/mL [Snapshot]; protocol-defined virologic failure [PDVF]) using linear/logistic regression with stepwise selection. A separate analysis evaluated baseline factors for association with treatment-adherent PDVF. RESULTS: In RC participants, higher baseline log10 HIV-1 RNA, lower number of fully active available antiretrovirals in initial optimized background therapy (OBT) and a lower overall susceptibility score to newly used antiretrovirals in initial OBT were associated with lower odds of virologic response at Week 96. Baseline gp120 substitutions and dolutegravir use were additional factors through Week 192. Other baseline factors, including CD4+ T-cell count <20 cells/mm3, HIV-1 RNA ≥100 000 copies/mL, antiretroviral therapy duration >20 years or gp120 substitutions, had low predictive value for treatment-adherent PDVF in RC participants (Week 96, 35%; Week 192, 39%). CONCLUSIONS: Multivariable analysis (MVA) identified several factors predictive of virologic response. No baseline factors were highly predictive of virologic failure at Weeks 96 or 192. Findings support the use of fostemsavir in diverse populations with MDR HIV-1.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Baseline factors associated with odds of virologic response (HIV‐1 RNA <40 copies/mL, Snapshot) at (a) Week 96 and (b) Week 192 in RC and NRC participants. Bolded odds ratios indicate significance ( p < 0.05). ARV, antiretroviral; DRV, darunavir; DTG, dolutegravir; NRC, Non‐randomized Cohort; OBT, optimized background therapy; OSS, overall susceptibility score; RC, Randomized Cohort. a 251 observations. b 92 observations. c In the NRC, the categories 0 and >0–1 were combined into a single category of 0 or 1. d S375H/I/M/N/Y, M426L or M434K.
非 KM Figure
FIGURE 2Baseline factors associated with odds of treatment‐adherent PDVF a at (a) Week 96 and (b) Week 192 in RC and NRC participants. Bolded odds ratios indicate significance ( p < 0.05). BID, twice daily; DRV, darunavir; DTG, dolutegravir; IC 50 , half‐maximal inhibitory concentration; NRC, Non‐randomized Cohort; OBT, optimized background therapy; OSS, overall susceptibility score; PDVF, protocol‐defined virologic failure; QD, once daily; RC, Randomized Cohort. a Defined as having treatment‐emergent genotypic (gp120 substitutions) or phenotypic changes at PDVF (temsavir IC 50 fold change >3‐fold increase) or reduced susceptibility (OSS or OSS‐new) to any agents in initial OBT. b 251 observations. c 92 observations.
非 KM Figure